Effect of erlotinib combined with cisplatin on IL‑6 and IL‑12 in mice with Lewis lung cancer

Zhang,Xu; Chen,Jinliang; Jin,Hongsong; Zhao,Wei; Chang,Zhibo; Wu,Huijing

doi:10.3892/ol.2020.11632

Effect of erlotinib combined with cisplatin on IL‑6 and IL‑12 in mice with Lewis lung cancer

Authors:
- Xu Zhang
- Jinliang Chen
- Hongsong Jin
- Wei Zhao
- Zhibo Chang
- Huijing Wu
View Affiliations

Affiliations: Department of Thoracic Oncology, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China, Department of Oncology, The People's Hospital of Taizhou, Taizhou, Jiangsu 225300, P.R. China, Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, P.R. China, Department of Thoracic Surgery, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Medical Oncology, Radio‑Chemotherapy Center, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
Published online on: May 18, 2020 https://doi.org/10.3892/ol.2020.11632
Pages: 902-906
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of erlotinib combined with cisplatin on tumor growth, interleukin‑6 (IL‑6) and interleukin‑12 (IL‑12) in mice with Lewis lung cancer (LLC) was investigated. Forty‑four pure inbred SPF C57BL/6J mice were modeled for LLC and randomized into groups A, B, C and D (n=11 each group). Mice in group A were given normal saline, group B was given erlotinib, group C was given cisplatin injection and group D erlotinib combined with cisplatin. Tumor growth of the mice was observed and the tumor mass was measured. Serum IL‑6 and IL‑12 levels were measured by enzyme‑linked immunosorbent assay (ELISA) 40 days later. At different time‑points after medication, tumor volume in group D was significantly lower than that in groups A, B and C (P<0.05), and that in groups B and C was significantly lower than that in group A (P<0.05), whereas there was no significant difference between groups B and C (P>0.05). Tumor mass in groups B, C and D was significantly lower than that in group A (P<0.05), and that in group D was significantly lower than that in groups B and C (P<0.05), whereas there was no significant difference between groups B and C (P>0.05). Compared with groups B and C, mice in group D had significantly lower IL‑6 level (P<0.05), but significantly higher IL‑12 level (P<0.05). There was no significant difference in IL‑6 and IL‑12 levels between groups B and C (P>0.05). In conclusion, erlotinib combined with cisplatin can inhibit the tumor growth of mice with LLC, and inhibition of IL‑6 level and upregulation of IL‑12 level may be one of its therapeutic mechanisms.

View Figures

View References

1	Cetta F, Renieri A and Frullanti E: Germline mutations in lung cancer and personalized medicine. Fam Cancer. 17:429–430. 2018. View Article : Google Scholar : PubMed/NCBI
2	Minguet J, Smith KH and Bramlage P: Targeted therapies for treatment of non-small cell lung cancer - Recent advances and future perspectives. Int J Cancer. 138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
3	Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al OAK Study Group, : Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
4	Kaplan JA, Liu R, Freedman JD, Padera R, Schwartz J, Colson YL and Grinstaff MW: Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. Biomaterials. 76:273–281. 2016. View Article : Google Scholar : PubMed/NCBI
5	Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al CheckMate 026 Investigators, : First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
6	Liu H and Song Y: MDT is still important in the treatment of early stage lung cancer. J Thorac Dis. 10 (Suppl 33):S3984–S3985. 2018. View Article : Google Scholar : PubMed/NCBI
7	Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, et al: Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 28:1532–1539. 2017. View Article : Google Scholar : PubMed/NCBI
8	Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lu S, Yu Y and Yang Y: Retrospect and prospect for lung cancer in China: Clinical advances ofimmune checkpoint inhibitors. Oncologist. 24 (Suppl 1):S21–S30. 2019. View Article : Google Scholar : PubMed/NCBI
10	Korytowsky B, Radtchenko J, Nwokeji ED, Tuell KW, Kish JK and Feinberg BA: Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies. Am J Manag Care. 24 (Suppl 20):S439–S447. 2018.PubMed/NCBI
11	Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011. View Article : Google Scholar : PubMed/NCBI
12	Bharti R, Dey G and Mandal M: Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. Cancer Lett. 375:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
13	Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P and Becher B: New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22:237–246. 2015. View Article : Google Scholar : PubMed/NCBI
14	Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, et al: Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 123:91–98. 2018. View Article : Google Scholar : PubMed/NCBI
15	Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T and Saiki I: Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer. 79:1121–1126. 1999. View Article : Google Scholar : PubMed/NCBI
16	Ogden BE, Pang William W, Agui T and Lee BH: Laboratory animal laws, regulations, guidelines and standards in China Mainland, Japan, and Korea. ILAR J. 57:301–311. 2016. View Article : Google Scholar : PubMed/NCBI
17	Karachaliou N, Fernandez-Bruno M, Bracht JWP and Rosell R: Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. Transl Lung Cancer Res. 7:691–702. 2018. View Article : Google Scholar : PubMed/NCBI
18	Berland L, Heeke S, Humbert O, Macocco A, Long-Mira E, Lassalle S, Lespinet-Fabre V, Lalvée S, Bordone O, Cohen C, et al: Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. J Thorac Dis. 11 (Suppl 1):S71–S80. 2019. View Article : Google Scholar : PubMed/NCBI
19	Kim YH: Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N Engl J Med. 380:989–990. 2019. View Article : Google Scholar : PubMed/NCBI
20	Sasaki T, Seto T, Yamanaka T, Kunitake N, Shimizu J, Kodaira T, Nishio M, Kozuka T, Takahashi T, Harada H, et al: A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Br J Cancer. 119:675–682. 2018. View Article : Google Scholar : PubMed/NCBI
21	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al KEYNOTE-024 Investigators, : Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
22	Furugaki K, Fukumura J, Iwai T, Yorozu K, Kurasawa M, Yanagisawa M, Moriya Y, Yamamoto K, Suda K, Mizuuchi H, et al: Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. Int J Cancer. 138:1024–1032. 2016. View Article : Google Scholar : PubMed/NCBI
23	Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B and Akerley W: Tivantinib in combination with erlotinib versus erlotinib alone for EGFR-Mutant NSCLC: An exploratory analysis of the phase 3 MARQUEE study. J Thorac Oncol. 13:849–854. 2018. View Article : Google Scholar : PubMed/NCBI
24	Lee JG and Wu R: Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. PLoS One. 7:e485322012. View Article : Google Scholar : PubMed/NCBI
25	Kumari N, Dwarakanath BS, Das A and Bhatt AN: Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
26	Li Q, Virtuoso LP, Anderson CD and Egilmez NK: Regulatory rebound in IL-12-treated tumors is driven by uncommitted peripheral regulatory T cells. J Immunol Volume? 1293–1300. 2015. View Article : Google Scholar
27	Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, Daliri S, Chang SH, Ochoa CE, Hanash S, et al: IL-6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras mutant lung cancer. Cancer Res. 76:3189–3199. 2016. View Article : Google Scholar : PubMed/NCBI
28	Li G and Lu B: Patients come first - the direction of lung cancer treatment. J Thorac Dis. 10:E714–E715. 2018. View Article : Google Scholar : PubMed/NCBI